American States Water Company vs Viatris Inc — how do they compare? American States Water Company trades at $87.85 (market cap $3.47B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 5.4× American States Water Company's market cap, and Viatris Inc pays the higher dividend (2.95%). Which is the better fit depends on your goals.
| AWR | VTRS | |
|---|---|---|
Market Cap | $3.47B | $18.69B |
Sector | Utilities | Health |
52-Week High | $89.28 | $17.86 |
52-Week Low | $70.10 | $9.49 |
Enterprise Value | $4.37B | $30.80B |
Dividend Yield | 2.49% | 2.95% |
Signals from Pluang's Aura AI — not financial advice
AWR trades at $87.95, up 1.59% on the day, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $1.09 versus $0.915 expected, driven by water rate increases and revenue growth. Recent news highlights its 71-year dividend growth streak and an 8.2% dividend hike announced in July 2026. Financials show solid profitability with a 20.52% net income margin and ROE of 13.62%, though valuation ratios like P/E of 23.92 are above sector averages.
Outlook is mixed: strong dividend history and earnings growth support income investors, but elevated valuation and mixed analyst consensus (20% buy, 50% hold, 30% sell) suggest limited near-term upside. Key risks include regulatory dependence on rate approvals and potential overvaluation relative to peers.
Viatris (VTRS) trades at $16.105, down 1.07% on the day, with a bearish technical signal and mixed fundamentals. Recent Q2 2026 earnings beat estimates with EPS of $0.69 and revenue growth of 5%, but the company posted a net loss of $3.51B in 2025. Positive developments include FDA approval for Gwyn Lo and a raised 2026 outlook, though debt remains elevated at $14.04B long-term.
Outlook is cautious; while operational cash flow is strong at $2.32B and dividends provide income, persistent net losses and high P/E of 236.2 signal overvaluation risks. Analyst consensus leans Hold (61.54%), with upside potential if turnaround gains traction, but investors face headwinds from generic drug pricing pressures and execution challenges.
Trailing returns across standard periods
Latest headlines on both assets
American States Water provides water and electric services to over one million people in the U.S. It also manages water and wastewater systems for various military bases under long-term privatization contracts.
Read more on AWR →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →